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Abstract
Objective: The American Diabetes Association and the Society of Critical Care Medicine recommend moni-
toring blood glucose (BG) every 1-2 hours in patients receiving insulin infusion to guide titration of insulin 
infusion to maintain serum glucose in the target range; however, this is based on weak evidence. We evaluated 
the compliance of hourly BG monitoring and relation of less frequent BG monitoring to glycemic status. 
Materials and Methods: Retrospective chart review performed on 56 consecutive adult patients who received 
intravenous insulin infusion for persistent hyperglycemia in the ICU at Saint Vincent Hospital, a tertiary 
care community hospital an urban setting in Northeast region of USA. The frequency of fingerstick blood 
glucose (FSBG) readings was reviewed for compliance with hourly FSBG monitoring per protocol and the 
impact of FSBG testing at different time intervals on the glycemic status. Depending on time interval of 
FSBG monitoring, the data was divided into three groups: Group A (<90 min), Group B (91-179 min) and 
Group C (≥180 min). Results: The mean age was 69 years (48% were males), 77% patients had preexisting type 
2 diabetes mellitus (T2DM). The mean MPM II score was 41. Of the 1411 readings for BG monitoring on 
insulin infusion, 467 (33%) were in group A, 806 (57%) in group B and 138 (10%) in group C; hourly BG 
monitoring compliance was 12.6%. The overall glycemic status was similar among all groups. There were 14 
(0.99%) hypoglycemic episodes observed. The rate of hypoglycemic episodes was similar in all three groups 
(p=0.55).  Conclusion: In patients requiring insulin infusion for sustained hyperglycemia in ICU, the risk of 
hypoglycemic episodes was not significantly different with less frequent BG monitoring. The compliance to 
hourly blood glucose monitoring and ICU was variable, and hypoglycemic episodes were similar across the 
groups despite the variation in monitoring. Significance of the Study: The importance of glycemic control in 
ICU has been well established and it is a resource intensive venture. However, there are no major studies 
highlighting the most optimal time interval for blood glucose checks in critically ill patients on insulin infu-
sion. With this study we hypothesize that time duration between blood glucose checks can be increased safely 
without any untoward effects. Our study provides evidence for effective resource management with reducing 
the time spent with every glucose check and directly translating into high value care. 
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As a part of this pilot study, retrospective data 
collection and analysis was performed for 56 patients 
admitted to the ICU from May 1, 2014 through 
November 30, 2014 who required intravenous insulin 
infusion for persistent hyperglycemia (two consecu-
tive blood glucose reading ≥180 mg/dL in patients 
with or without preexisting T2DM). Data was 
obtained from the chart review through electronic 
medical records.  The insulin infusion protocol used 
in our ICU was developed after the publication of 
the NICE-SUGAR trial (8). The glycemic target was 
140-180 mg/dL, which was intended to be achieved 
by insulin infusion rate adjustment based on hourly 
FSBG readings and not on the basis of rate of change 
of BG (see Supplement 1 for protocol). Study was 
approved by institution review board (IRB num-
ber 2015-73, July 2th 2015 by Metrowest Medical 
Center IRB). 
Dysglycemic episodes included hypoglycemia 
(BG values of less than 70 mg/dL) and hyperglyce-
mia (BG values of more than or equal to 180 mg/dL). 
Inclusion criteria included all the consecutive patients 
admitted to medical ICU with hyperglycemia requir-
ing insulin infusion for blood glucose control during 
the study period. Patients with diabetic ketoacidosis, 
hyperglycemic hyperosmolar states and those admitted 
to cardiac surgery service were excluded since our ICU 
has separate treatment protocols for such patients. BG 
levels were measured using a standard hospital glu-
cometer (StatStrip Xpress©2 Glu, Hospital Glucose 
Monitoring System, Nova Biomedical Corporation, 
Waltham, MA, USA). The blood glucose values were 
automatically transmitted to the electronic medical 
record system through a glucose meter dock, elimi-
nating any human error of value imputation.  Eligible 
patients were monitored through the ICU stay till the 
time they required insulin infusion.
Introduction 
Intravenous insulin infusion guided by frequent 
fingerstick blood glucose (FSBG) monitoring is the 
preferred method of hyperglycemia management in 
the intensive care unit (ICU). The American Diabetes 
Association (ADA) and the Society of Critical Care 
Medicine (SCCM) recommend monitoring FSBG 
every 1-2 hours in patients receiving insulin infusion 
to prevent hypoglycemic events by guiding appropri-
ate titration of insulin infusion (1, 2). However, this 
recommendation is based on expert opinion. To the 
best of our knowledge, there have been no studies to 
support 1-2 hourly FSBG testing as the optimal time 
interval to maintain stable glycemic control in patients 
receiving intravenous insulin infusion. 
Reduced frequency of blood glucose (BG) test-
ing should minimize discomfort from frequent painful 
finger sticks, reduction of nursing burden and health-
care cost; however, attainment of optimal glycemic sta-
tus must not be compromised by less frequent FSBG 
monitoring.  The importance of optimal glycemic con-
trol in critically ill patients cannot be over-emphasized 
as both hypoglycemia and hyperglycemia are associ-
ated with poor outcomes (3-5).   Nonetheless, achiev-
ing glycemic goals in critically ill patients is often 
hard to achieve as the process involves multiple fac-
tors including nursing commitment to frequent FSBG 
checks, implementation of a well developed and tested 
intravenous insulin infusion protocol and effective 
resource management. 
Although many studies undertake the difficult 
task to assess the glycemic control in critically ill 
patients, we were unable to find any studies comment-
ing directly on the compliance of the implemented 
protocol (5-7). We intended to evaluate the compli-
ance of the current protocol as a measure of current 
understanding of the nursing staff. This is important, 
as any change in the protocol directly affects the nurs-
ing staff and subsequently translating into patient care 
issues. 
Thus, we aimed to evaluate the compliance with 
1 hourly FSBG readings required by our protocol for 
patients receiving intravenous insulin in the ICU to 
treat hyperglycemia. In addition, we also studied the 
Acta Biomed 2021; Vol. 92, N. 1: e2021036  3
and were not readmitted for the sole purpose of treat-
ing hyperglycemia with an insulin infusion during the 
same hospital admission. Baseline characteristics are 
shown in Table 1, including ICU admission diagno-
ses and relevant clinical interventions. Mean age was 
69.5 years; 48% patients were males, 77% patients had 
preexisting diabetes and mean MPM II score was 40.7.
Glycemic Control
Of the 1411 time intervals for BG monitoring 
in 56 patients while on insulin infusion, 467 readings 
(33%) were in group A (≤90 min), 806 readings (57%) 
in group B (91-179 min) and 138 readings (10%) in 
group C (≥180 min); hourly BG monitoring com-
pliance was 12.6% (178/1411). Fourteen (0.99%) of 
the 1411 readings were in the hypoglycemic range 
(<70 mg/dL) as defined above. The frequency of hypo-
glycemic episodes were similar in all three groups 
(p=0.55) and post hoc analysis between the groups was 
Baseline characteristics were obtained including 
age, sex, ethnicity, history and type of diabetes, body 
mass index (BMI), and mortality probability model 
(MPM) II score at ICU admission to estimate the 
severity of illness. We focused on six clinical interven-
tions including diagnosis of sepsis during the admis-
sion, surgical versus medical patient, previous use of 
insulin, concurrent corticosteroid therapy, renal dys-
function and nutritional status of the patient (fasting 
state, enteral or parenteral feeding).
Based on the time interval of FSBG testing, the 
data was divided into three groups: Group A (≤90 min), 
Group B (91-179 min) and Group C (≥180 min). 
However, since groups were divided based on fre-
quency of blood glucose testing one patient could 
fall into more than one groups. For example a single 
patient can fall into more than one groups based on 
the frequency of blood glucose monitoring (≤90 min, 
91-179 min or ≥180 min) during the course of ICU 
stay requiring insulin infusion. 
Statistical Analysis
Mortality probability model (MPM) II at ICU 
admission was used to estimate the severity of illness 
and prognosis. Except where noted, all the clinical data 
was expressed as means ± standard deviation or as a 
percentage.
Two way ANOVA was used to calculate any dif-
ference in dysglycemic events between groups A, B 
and C. The data was presented as means ± standard 
deviation (SD) or medians (with interquartile ranges), 
unless otherwise indicated. Data analysis was per-
formed using the software Statistical Package for the 
Social Science (SPSS) version 16 (SPSS Inc. Chicago, 
IL, USA). P <0.05 was considered statistically signifi-
cant. 
Results
A total of 215 patients who were admitted to the 
ICU and required insulin infusions were screened. 
Fifty-six patients met the inclusion criteria. All 56 
patients were discharged or transferred from the ICU 
TABLE 1. Baseline Characteristics
Characteristic Study Patients
n 56
Age 69.5 ± 9.5 (SD)
Male Sex 27 (48.2%)
Ethnicity Caucasian 50 (89.3%)
BMI (kg/m2) 32.6 ± 9.4 
Mortality Probability Model II 
score (MPM II)
40.7 ± 27.2
History of Diabetes 43 (76.8%)
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not statistically significant. There was a trend of higher 
hypoglycemic events in Group C (FSBG check ≥180 
mins) vs. Group A (FSBG check ≤90 mins) (p= 0.08). 
The co-efficient of variation for blood glucose (glucose 
CV %) was 38.79% with standard deviation of ± 70.67 
mg/dL for all the patients. 
There was a total of 14 patients (no patient had 
more than 1 episode of hypoglycemia) who experi-
enced hypoglycemic episodes while on insulin infusion 
combined in all 3 groups (Group A, B and C). Group 
A had 0.85% (n=4), group B had 0.74% (n=6) and 
group C had 2.89 % (n=4) readings of hypoglycemia 
out of 467, 806 and 138 total readings in each group 
respectively. There was no statistically significant dif-
ference in episodes of hypoglycemia comparing three 
groups, corrected for individual patient using 2 way 
ANOVA (Figure 1). Cumulative mortality was noted 
to be 36% (20 of 56 studied patients, expected 40.7% 
as per MPM II calculations). There was no statistically 
significant difference among the three groups in terms 
of mortality or length of stay in the hospital. There was 
no statistical difference in hypoglycemic events with 
strict compliance of FSBG monitoring per protocol 
versus non-compliant (Figure 2). 
Effect of Relevant Clinical Variables 
During the analysis, we considered six clinically 
relevant variables namely diagnosis of sepsis during the 
Figure 1. Differences in glycemic episodes (hypoglycemia vs 
normoglycemia, 70–180 mg/dL) between the three interval 
groups A (<90 min), B (90-179 min) and C (≥180 min) cor-
rected for individual patient (P value 0.553; 2 way ANOVA).
Figure 2. Blood Glucose monitoring strict compliance group 
(Group A) vs non-compliance group combined (Group B and 
Group C combined), no statistically significant difference in 
terms of hypoglycemic episodes.
current ICU admission, whether the patient was a sur-
gical versus medical ICU patient, previous history of 
insulin use, concomitant corticosteroid therapy, renal 
dysfunction and nutritional status (nil per oral, enteral 
nutrition or parenteral nutrition). None of the clinical 
variables were found to have any correlation between 
hypoglycemic events and the 3 interval groups of 
FSBG measurements. Further analysis showed a rapid 
decline in blood glucose levels in the first 16 hours of 
starting insulin infusion followed by subsequent sta-
bilization as shown in Figure 3. The rate of change of 
blood glucose levels (mg/dL/min) followed a similar 
trend in all three groups. There was no significant dif-
ference in FSBG measurement compliance before or 
after stabilization of blood glucose at 16 hours of insu-
lin infusion. 
Discussion
Hyperglycemia in critically ill patients results 
from increased physiological demands secondary to 
release of cytokines and counter-regulatory hormones, 
use of corticosteroids and sympathomimetic drugs 
which trigger and worsen hyperglycemia by increasing 
insulin resistance and gluconeogenesis (4, 9). Only 77 
percent of our study patients had pre-existing diabetes 
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and the rest developed hyperglycemia secondary to the 
critical illness.
Critical illness-induced dysglycemia (CID), the 
term proposed for glucose dysregulation (hypergly-
cemia, hypoglycemia and glucose variability) in criti-
cally ill patients, has been linked to poorer outcomes 
(2, 4, 5, 10-14). Most experts agree with the recom-
mendation to keep the BG between 140-180 mg/dL 
in critically ill patients. With the advent of increasing 
use of insulin infusion for hyperglycemia in critically ill 
patients, continuing education for the healthcare staff 
and frequent BG monitoring becomes quintessential 
to ensure patient safety. 
Given the rapidity of onset, short duration of 
action and easy titration, intravenous infusion is the 
preferred route of insulin administration to keep BG 
within the target range in critically ill patients. Multi-
ple computerized and paper-based protocols have been 
validated for use in different settings, and computer-
ized protocols may provide superior glycemic control 
and improved protocol adherence (15-20). Surpris-
ingly, despite such a wealth of literature, there have 
been no major clinical trials utilizing insulin infusion 
that clearly delineate the most appropriate interval for 
blood glucose checks for patients on intravenous insu-
lin infusion. Consensus recommendation released by 
Jacobi et al. to check blood glucose every 1-2 hours 
was based on “very low, quality of evidence” (2). ADA 
and American Association of Clinical Endocrinolo-
gists (AACE) recommend hourly BG checks for 
patients receiving intravenous insulin therapy, except 
for patient with stable BG in a desirable range for 
whom the frequency may be extended to every 2 hours 
(11). Liberal 4 hourly BG testing frequency increases 
the risk of hypoglycemia to almost 10% (13, 21, 22).  
Our study showed no statistically significant dif-
ference in hypoglycemic episodes when the time inter-
val in FSBG monitoring was increased. The insulin 
infusion protocol established by Goldberg et al., was 
found to be cumbersome and difficult to implement 
in our setting as it considers the rate of change as well 
as absolute glucose values to titrate the dose of insulin 
infusion (12). In contrast, the protocol developed by 
and used in our study was based only on absolute blood 
glucose values to help with the titration of insulin 
infusion (Supplement 1). Important considerations for 
implementing a protocol for management of hyper-
glycemia include glycemic targets, staff motivation in 
optimizing glycemic control, frequency of blood glu-
cose monitoring and availability of resources for blood 
glucose checks and documentation. 
In our study, the strict compliance with hourly 
FSBG check (Group A) was only 12.6%. Potential 
barriers that contributed to the poor compliance were 
nursing burden in terms of time consumed in FSBG 
monitoring and adjusting treatment appropriately, 
healthcare cost including the cost of non-reusable and 
reusable equipment and indirect cost of nursing time 
utilized. However these barriers can only be postu-
lated retrospectively since the study was not designed 
to assess these issues individually. 
Commonly encountered barriers to the imple-
mentation of an insulin infusion protocol include 
ambiguity of targets of glycemic control, low nurse-to-
patient ratio, practitioner resistance to adopt change, 
and a lack of organizational and financial support. The 
time spent on blood glucose monitoring in the ICU 
setting is often overlooked. Each blood glucose check 
may require up to 7 minutes by a trained nurse which 
includes measurement of blood glucose, recording of 
the measurement, followed by intervention (23). In an 
ICU with nurse to patient ratio of 1:1.5, and a  nurse 
is actively caring for 2 patients on insulin infusion, she 
would spend 2 hours out of a 12 hour shift merely on 
Figure 3. Change in blood glucose (mg/dL) with time in min-
utes for all patients.
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glucose checks, which could be even greater in ICUs 
having higher nurse to patient ratio. Thus, safely 
increasing the time interval between glucose checks 
without significantly increasing the risk of hypoglyce-
mia can be a point of high value care that will have a 
huge impact on the healthcare system.
Our study showed no statistically significant dif-
ference in hypoglycemic episodes when FSBG checks 
were done at the intervals of <90 minutes, 90-180 
minutes or > 180 minutes. Within the group where 
FSBG checks were more than180 minutes (Group 
C), the episodes of hypoglycemia were more frequent 
than the other two groups and showed a trend towards 
statistical significance (p = 0.08). This may not have 
reached statistical significance due to the small sample 
size in our study and may benefit by being studied in 
larger studies. 
Well-tried protocols achieve desirable glycemic 
control within 3-12 hours, however reported incidence 
of hypoglycemia may vary from less than 1% to 20% 
(17, 24). In our study, we found that there was a rapid 
decline in the BG levels in the first 16 hours, followed 
by stabilization. However the distribution of hypogly-
cemic episodes did not follow a pattern and the differ-
ence in number of episodes before or after stabilization 
of blood glucose was not statistically significant. Pas-
sarelli et al. commented in their article about a direct 
correlation with protocol violation and episodes of 
hypoglycemia (12). Despite the time variation and dif-
ference in level of compliance amongst the three study 
groups, the overall incidence of hypoglycemia was only 
0.7%. Hypoglycemia is linked with the risk factors of 
history of diabetes mellitus, severity of illness, use of 
ionotropic drugs, renal insufficiency and previous use 
of insulin (4, 25). In our study, the impact of ongoing 
sepsis, concurrent use of steroids, renal dysfunction, 
and current nutritional status, severity of illness and 
past history of diabetes mellitus were considered; how-
ever, there was no statistical correlation found with any 
of these factors and the risk of hypoglycemia. 
Rood et al. introduced the idea of computerized 
and automated insulin infusion protocol in complex 
settings such as ICU to improve adherence to the 
protocol, improve quality of care and reduce the time 
intensive nature of the process (26). Our institution 
has introduced a similar model with an insulin infu-
sion calculator to auto-calculate the dose of insulin 
based on the glucose values and current rate of insu-
lin infusion (units/hour). Moving forward, the ideal 
insulin infusion protocol would be one that could be 
integrated into the current electronic medical record 
system, is user-friendly to the healthcare staff, allows 
for automated processing of the current blood glucose 
reading and is able to titrate the dose of insulin accord-
ingly to minimize the human error. Potential caveats 
to that would be erroneous readings, mechanical errors 
and varying nutrition or caloric intake of the patient. 
Limitations of the study include retrospective 
data collection from a single center mixed service ICU 
and poor compliance to hourly blood glucose monitor-
ing. In addition, this was a small sample with exclu-
sion of patients from cardio-thoracic surgery group 
and those presenting with DKA and hyperglycemic 
hyperosmolar state. Thus, the results cannot be gen-
eralized to all patients receiving insulin infusion for 
hyperglycemia. We also did not look at effect of our 
intervention in terms of length of stay and duration 
of insulin infusion requirement. Effect of vasopressors 
and steroid use was not studied in this group. Recently 
the definition of hypoglycemia has been revised to BG 
values of less than 54 mg/dL, however our results were 
analyzed keeping in mind the cutoff of 70mg/dL based 
on previous data.  
Conclusion
Despite a lack of strict compliance (12.6%) with 
hourly blood glucose monitoring in patients receiv-
ing insulin infusion to treat hyperglycemia, the risk of 
hypoglycemic episodes was not significantly different 
with less frequent BG monitoring. The compliance to 
hourly blood glucose monitoring and ICU was vari-
able, and hypoglycemic episodes were similar across 
the groups despite the variation in monitoring.
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APPENDIX: SUPPLEMENTARY FILE 1: Institutional Hyperglycemia Management Protocol 

